Abstract
Fanconi anemia (FA) is a rare inherited bone marrow failure syndrome (IBMFS). Affected individuals must be distinguished from relatives, patients with mosaicism must be identified, and patients with other IBMFS classified as non-FA. The diagnostic feature of FA is increased chromosomal breakage in blood lymphocytes cultured with diepoxybutane or mitomycin C. Here, we sought a method to uniquely identify patients with FA with mosaicism, using cells from participants in the National Cancer Institute IBMFS cohort. Lymphocytes were treated with diepoxybutane or mitomycin C, and metaphases scored for breaks and radials. Analyses included the percentage of cells with any aberration, breaks per cell, and breaks per aberrant cell. There were 26 patients with FA (4 mosaics), 46 FA relatives, and 62 patients with a non-FA IBMFS. By all analytic methods, patients with FA were abnormal compared with other groups. Those with FA mosaicism had more breakage than relatives or patients with non-FA IBMFS, but there was some individual overlap. The choices of clastogen are laboratory-dependent, but there was no method or analysis of lymphocytes that clearly distinguished all individuals mosaic for FA from relatives or patients with other IBMFS. Thus, genotyping remains the best method for providing absolute clarity.
Original language | English (US) |
---|---|
Pages (from-to) | 15-27 |
Number of pages | 13 |
Journal | Cytogenetic and Genome Research |
Volume | 144 |
Issue number | 1 |
DOIs | |
State | Published - Nov 19 2014 |
Keywords
- Chromosome breakage
- Diepoxybutane
- Fanconi anemia
- Inherited bone marrow failure
- Mitomycin C
ASJC Scopus subject areas
- Molecular Biology
- Genetics
- Genetics(clinical)